Targeted nanoparticles to deliver a multimodal peptide to head and neck tumors
Award amount
$258,009Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Asclepix Therapeutics, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- RC85LPKJ26P8
- Solicitation number
- PAR10-286
- Topic code
- NCI
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Immunoactivating Peptide AXT201 in Combination with Anti-PD-1 Antibody for Triple-Negative Breast Cancer
- Therapeutic peptide for hepatocellular carcinoma
- IND-enabling development of a biomimetic peptide drug for macular edema
- Development of a mimetic multimodal peptide for the treatment of macular edema
- Long-term anti-angiogenic activity of intravitreal ellipsoid particles for NVAMD
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
6 SBIR/STTR records share this UEI (2014–2019). Reported award amounts total $3,493,519. Reported amounts are not federal obligations.
Phases: Phase I, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services